Analysts: Keryx Biopharmaceuticals Inc (KERX.W)
KERX.W on CBOE When Trading NASDAQ Global Select Market
8.08USD
21 May 2013
8.08USD
21 May 2013
Price Change (% chg)
$0.14 (+1.76%)
$0.14 (+1.76%)
Prev Close
$7.94
$7.94
Open
$8.14
$8.14
Day's High
$8.14
$8.14
Day's Low
$8.02
$8.02
Volume
1,500
1,500
Avg. Vol
9,291
9,291
52-wk High
$9.97
$9.97
52-wk Low
$1.56
$1.56
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.10 | December | 22 May 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 4 | 4 | 4 | 4 |
| (2) OUTPERFORM | 5 | 4 | 4 | 4 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.56 | 1.50 | 1.50 | 1.50 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-13 | 8 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-13 | 8 | 2.50 | 20.00 | 0.00 | 0.00 |
| Year Ending Dec-13 | 8 | 9.50 | 27.00 | 7.00 | 9.89 |
| Year Ending Dec-14 | 8 | 52.60 | 92.35 | 10.20 | 52.38 |
| Earnings (per share) | |||||
| Quarter Ending Jun-13 | 8 | -0.10 | -0.06 | -0.12 | -0.07 |
| Quarter Ending Sep-13 | 8 | -0.08 | 0.15 | -0.13 | -0.08 |
| Year Ending Dec-13 | 8 | -0.32 | -0.07 | -0.40 | -0.23 |
| Year Ending Dec-14 | 8 | 0.07 | 0.84 | -0.40 | 0.25 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 5.83 | 7.00 | 1.17 | 20.00 |
| Quarter Ending Dec-12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Jun-12 | 0.30 | 0.00 | 0.30 | 100.00 |
| Quarter Ending Mar-12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | -0.01 | -0.03 | 0.02 | -347.76 |
| Quarter Ending Dec-12 | -0.08 | -0.09 | 0.02 | -20.00 |
| Quarter Ending Sep-12 | -0.07 | -0.08 | 0.01 | -9.74 |
| Quarter Ending Jun-12 | -0.09 | -0.06 | 0.03 | -36.37 |
| Quarter Ending Mar-12 | -0.12 | -0.13 | 0.01 | -7.17 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-13 | 2.50 | 2.50 | 0.67 | 0.50 | 0.00 |
| Year Ending Dec-13 | 9.50 | 9.50 | 7.17 | 18.31 | 9.89 |
| Year Ending Dec-14 | 52.60 | 53.52 | 39.39 | 39.39 | 52.38 |
| Earnings (per share) | |||||
| Quarter Ending Jun-13 | -0.10 | -0.10 | -0.08 | -0.08 | -0.07 |
| Quarter Ending Sep-13 | -0.08 | -0.08 | -0.08 | -0.07 | -0.08 |
| Quarter Ending Dec-13 | -0.32 | -0.32 | -0.25 | -0.23 | -0.23 |
| Quarter Ending Dec-14 | 0.07 | 0.08 | 0.02 | 0.02 | 0.25 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-13 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-13 | 0 | 0 | 0 | 1 |
| Year Ending Dec-13 | 0 | 0 | 0 | 1 |
| Year Ending Dec-14 | 0 | 1 | 2 | 0 |
| Earnings | ||||
| Quarter Ending Jun-13 | 0 | 0 | 0 | 5 |
| Quarter Ending Sep-13 | 0 | 0 | 0 | 5 |
| Year Ending Dec-13 | 0 | 0 | 0 | 6 |
| Year Ending Dec-14 | 0 | 1 | 1 | 4 |
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Earnings vs.
Estimates